Sign in
Taking peoplePhase 3

Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

Key facts

Who runs it
Alfasigma S.p.A.
Where
Belgium, Bulgaria, Czechia, France, Germany, Greece, Hungary, Italy, Poland, Spain, and United Kingdom48 sites in 11 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
65 people, planned
Started
21 May 2026
Expected to end
Jun 2027
Type of study
Interventional
Treatments tested
  • Filgotinib
Record updated
12 June 2026

Who can take part

Age
8 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Subject and/or parent/legal guardian must be able and willing to comply with the clinical study protocol requirements and must sign and date the ICF and assent (if required per local regulation) as approved by the Independent Ethics Committee / Institutional Review Board, prior to any screening evaluations
  • Female or male subject 8 to <18 years of age, on the date of signing the informed consent and assent (per local regulation) form
  • Subject must meet the ILAR classification and have moderately to severely active disease for one of the following categories that is not adequately controlled with his/her current therapy (see Protocol Appendix 1 for disease activity assessment criteria):; Extended oligoarthritis (i.e. affecting a total of more than 4 joints after the first 6 months of disease); RF-positive polyarthritis; RF-negative polyarthritis; PsA; ERA
  • Subject with intolerance or a history of inadequate response to at least one of the following medications for the treatment of pJIA, administered for at least 3 months, based on current treatment guidelines: conventional synthetic disease modifying anti rheumatic drugs (csDMARDs; including methotrexate) and/or biologic disease modifying anti-rheumatic drugs (bDMARDs) administered per local label, and/or non steroidal anti-inflammatory drugs for ERA and PsA subtypes
  • Female subject of childbearing potential who is sexually active and at risk for pregnancy must agree to use contraception/preventive exposure measures as described in the protocol

Who cannot take part

  • Subject with anterior uveitis (active or uncontrolled) ≤12 weeks prior to baseline
  • Subject with persistent oligoarthritis (i.e. affecting not more than 4 joints throughout the disease course)
  • Subject with any other rheumatic disease, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, or systemic lupus erythematosus)
  • Subject has an active infection. • Subject with a history of complicated herpes zoster infection (with multi dermatomal, disseminated, ophthalmic, or central nervous system involvement)
  • Subject has any condition or circumstances (including abnormalities in laboratory parameters) that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements
  • Subject with a body weight <15 kg
  • Subject with undifferentiated arthritis
  • Subject with systemic JIA

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 8 and 18 years old?

This trial has no sites in United States.

It has sites in 11 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.

The group in the trial

  • FilgotinibTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib in Children and Adolescents From 8 Years to Less Than 18 Years of Age With Polyarticular-course Juvenile Idiopathic Arthritis
Fit questions
Built from NCT07554495, who can take part
Record updated
12 June 2026